Senior Specialty Pharma Analyst Dewey Steadman joined Canaccord Genuity from Akorn, a large-cap specialty generic pharmaceutical company, where he was the executive director of Investor Relations. Prior to that, he was director of IR for Actavis plc. Prior to his investor relations career, Dewey worked on the Specialty Pharma teams at J.P. Morgan, Morgan Stanley, and RBC, alongside some of the top analysts in the field. Dewey earned a dual degree in chemistry/biochemistry and in biology/molecular biology from the University of West Florida, and an MBA from the Rollins College Crummer Graduate School of Business. He is a CFA charterholder and based in NY.